Publish date:

Boston Scientific Gets FDA Approval for SVG Treatment

The companys FilterWire EX Embolic Protection System will be launched next week in the U.S.

Medical device developer

Boston Scientific

(BSX) - Get Boston Scientific Corporation Report

said it received clearance from the Food and Drug Administration to market its saphenous vein graft, or SVG, disease treatment.

TheStreet Recommends

The company's FilterWire EX Embolic Protection System will be launched next week in the U.S. SVG disease occurs when saphenous veins harvested from the leg for use in coronary artery bypass graft surgery develop atherosclerosis.

Shares of the company were up 0.7% at $56.43 in late morning trading Monday.